Spivak JL The chronic myeloproliferative disorders: clonality and clinical heterogeneity. In: Seminars in hematology, 2004. Elsevier, pp 1–5

Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23(33):8520–8530

Article  CAS  PubMed  Google Scholar 

Pettit K, Rezazadeh A, Atallah EL, Radich J (2022) Management of myeloproliferative neoplasms in the molecular era: from research to practice. Am Soc Clin Oncol Educational Book 42:595–613

Article  Google Scholar 

Patel AB, Vellore NA, Deininger MW (2016) New strategies in myeloproliferative neoplasms: the evolving genetic and therapeutic landscape. Clin Cancer Res 22(5):1037–1047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435

Article  PubMed  PubMed Central  Google Scholar 

Plosker GL (2015) Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs 75:297–308

Article  CAS  PubMed  Google Scholar 

Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O’Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL (2023) Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol 41(19):3534

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA (2011) FDA approves treatment for patients with rare bone marrow disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder. Accessed 14 June 2024

FDA (2019) FDA approves ruxolitinib for acute graft-versus-host disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease Accessed 14 June 2024

FDA (2022) FDA Approves Ruxolitinib for Acute Graft-Versus-Host Disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease

FDA (2011) FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older

Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. In: Mayo Clinic Proceedings, vol 12. Elsevier, pp 1188–1191

Masarova L, Verstovsek S, Kantarjian H, Daver N (2017) Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol 10(10):903–914

Article  CAS  PubMed  Google Scholar 

Cervantes F (2014) How I treat myelofibrosis. Blood 124(17):2635–2642

Article  CAS  PubMed  Google Scholar 

Gowin KL, Mesa RA (2015) Profile of Pomalidomide and its potential in the treatment of myelofibrosis. Ther Clin Risk Manag :549–556

Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22–33

Article  CAS  PubMed  Google Scholar 

Iurlo A, Cattaneo D (2017) Treatment of myelofibrosis: old and new strategies. Clin Med Insights: Blood Disorders 10:1179545X17695233

PubMed  PubMed Central  Google Scholar 

Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS (2010) Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. J Am Soc Hematol 116(22):4436–4438

CAS  Google Scholar 

Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S (2009) Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27(28):4760

Article  PubMed  PubMed Central  Google Scholar 

Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang Z, Pierce S, Kadia T, Sasaki K, Borthakur G (2015) Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058–1063

CAS  PubMed  PubMed Central  Google Scholar 

Charlier B, Marino L, Dal Piaz F, Pingeon M, Coglianese A, Izzo B, Serio B, Selleri C, Filippelli A, Izzo V (2019) Development and validation of a reverse-phase high-performance liquid chromatography with fluorescence detection (RP-HPLC-FL) method to quantify ruxolitinib in plasma samples. Anal Lett 52(8):1328–1339

Article  CAS  Google Scholar 

Li Z, Sun N, Zhang Q, Ma H-h, Wang D, Zhao Y-z, Yang C-q, Zhang R, Zhao L-b (2022) Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis. Anal Methods 14(23):2293–2303

Article  PubMed  Google Scholar 

Veeraraghavan S, Thappali S, Viswanadha S, Chennupati S, Nalla S, Golla M, Vakkalanka S, Rangasamy M (2014) Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC–MS/MS: application to a pharmacokinetic study. J Pharm Biomed Anal 94:125–131

Article  CAS  PubMed  Google Scholar 

Pressiat C, Huynh H-H, Ple A, Sauvageon H, Madelaine I, Chougnet C, Le Maignan C, Mourah S, Goldwirt L (2018) Development and validation of a simultaneous quantification method of ruxolitinib, vismodegib, olaparib, and pazopanib in human plasma using liquid chromatography coupled with tandem mass spectrometry. Ther Drug Monit 40(3):337–343

Article  CAS  PubMed  Google Scholar 

Ranganathan P, Gunasekaran V, Singhvi I, Ansari MJ (2019) Development and validation of Lenalidomide in human plasma by LC-MS/MS. Saudi J Biol Sci 26(7):1843–1847

Article  CAS  PubMed  Google Scholar 

Neşetoglu N, Kaplan C, Aslan SS, Ünal DÖ (2020) A simple and rapid LC-MS/MS method for therapeutic drug monitoring of lenalidomide. Pak J Anal Environ Chem 21(1):19–26

Article  Google Scholar 

Gopinath R, Narenderan S, Kumar M, Babu B (2019) Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of lenalidomide in human plasma and its application on bioequivalence studies. J Anal Sci Technol 10(1):33

Article  Google Scholar 

Wang B, Qiang W, Yi J, Gao S, Meng B, Mu Y, Wang B, Wang Z, Tao X (2023) Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS. J Pharmacol Toxicol Methods 120:107250

Article  CAS  PubMed  Google Scholar 

Shu C, Zeng T, Gao S, Xia T, Huang L, Zhang F, Chen W (2016) LC–MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients. J Chromatogr B 1028:111–119

Article  CAS  Google Scholar 

ICH (2022) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. In ICH Harmonised Guideline; Bioanalytical Method Validation and Study Sample Analysis: M10, ICH. Geneva, Switzerland, 2022

Gałuszka A, Migaszewski ZM, Konieczka P, Namieśnik J (2012) Analytical Eco-scale for assessing the greenness of analytical procedures. TRAC Trends Anal Chem 37:61–72

Article  Google Scholar 

Płotka-Wasylka J (2018) A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta 181:204–209

Article  PubMed  Google Scholar 

Pena-Pereira F, Wojnowski W, Tobiszewski M (2020) AGREE—Analytical GREEnness metric approach and software. Anal Chem 92(14):10076–10082

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma S, Singh N, Ankalgi AD, Rana A, Ashawat MS (2021) Modern trends in analytical techniques for method development and validation of pharmaceuticals: a review. J Drug Delivery Ther 11(1–s):121–130

Article  CAS  Google Scholar 

Kumar D, Kumar A, Kumar V, Raj A, Rai RRM, Baliyan V, Kumar N (2023) A comprehensive review on analytical method development using rp-hplc and recent advances in pharmaceutical applications. J Res Appl Sci Biotechnol 2(2):53–60

Article  Google Scholar 

Sayed AY, Khalil NY, Almomen A, Alzoman NZ, Almehizia AA, Darwish IA (2021) A highly sensitive nonextraction-assisted HPLC method with fluorescence detection for quantification of duvelisib in plasma samples and its application to pharmacokinetic study in rats. Drug Design, Development and Therapy, pp 2667–2677

Google Scholar 

Darwish IA, Khalil NY (2023) Development and comparative evaluation of two different label-free and sensitive fluorescence platforms for analysis of olaparib: a recently FDA-approved drug for the treatment of ovarian and breast cancer. Molecules 28(18):6524

Article  CAS  PubMed  PubMed Central  Google Scholar 

Appeldoorn TYJMTHO, Morsink LM, Hooge MNL, Touw DJ (2023) Pharmacokinetics and Pharmacodynamics of Ruxolitinib: a review. Clin Pharmacokinet 62(4):12

Article  Google Scholar 

Rozewski DM, Herman SE, Towns WH, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D (2012) Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J 14:872–882